NDC 0009-7224
Atgam
Equine Thymocyte Immune Globulin
Atgam is a Intravenous Injection, Solution in the Plasma Derivative category. It is labeled and distributed by Pharmacia & Upjohn Company Llc. The primary component is Equine Thymocyte Immune Globulin.
| Product ID | 0009-7224_0d478b52-6fdd-4d6e-bdb2-535b4b40d0eb |
| NDC | 0009-7224 |
| Product Type | Plasma Derivative |
| Proprietary Name | Atgam |
| Generic Name | Equine Thymocyte Immune Globulin |
| Dosage Form | Injection, Solution |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 1981-11-17 |
| Marketing Category | BLA / BLA |
| Application Number | BLA103676 |
| Labeler Name | Pharmacia & Upjohn Company LLC |
| Substance Name | EQUINE THYMOCYTE IMMUNE GLOBULIN |
| Active Ingredient Strength | 50 mg/mL |
| Pharm Classes | Immunoglobulin G [EPC],Lymphocyte Function Alteration [PE],Increased T Lymphocyte Destruction [PE],Antibody-Surface Protein Interactions [MoA],Immunoglobulins [CS] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2022-12-31 |
Packaging
NDC 0009-7224-02
5 AMPULE in 1 CARTON (0009-7224-02) > 5 mL in 1 AMPULE (0009-7224-01)
| Marketing Start Date | 1981-11-17 |
| NDC Exclude Flag | N |
| Sample Package? | N |
NDC SPL Data Element Entries
NDC 0009-7224-02 [00009722402]
Atgam INJECTION, SOLUTION
| Marketing Category | BLA |
| Application Number | BLA103676 |
| Product Type | PLASMA DERIVATIVE |
| Billing Unit | ML |
| Marketing Start Date | 1981-11-17 |
NDC 0009-7224-01 [00009722401]
Atgam INJECTION, SOLUTION
| Marketing Category | BLA |
| Application Number | BLA103676 |
| Product Type | PLASMA DERIVATIVE |
| Billing Unit | ML |
| Marketing Start Date | 2013-11-08 |
Drug Details
Active Ingredients
| Ingredient | Strength |
|---|---|
| EQUINE THYMOCYTE IMMUNE GLOBULIN | 50 mg/mL |
Pharmacological Class
- Immunoglobulin G [EPC]
- Lymphocyte Function Alteration [PE]
- Increased T Lymphocyte Destruction [PE]
- Antibody-Surface Protein Interactions [MoA]
- Immunoglobulins [CS]
- Immunoglobulin G [EPC]
- Lymphocyte Function Alteration [PE]
- Increased T Lymphocyte Destruction [PE]
- Antibody-Surface Protein Interactions [MoA]
- Immunoglobulins [CS]
Trademark Results [Atgam]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 ATGAM 73095048 1074848 Live/Registered |
UPJOHN COMPANY, THE 1976-12-08 |
© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.